| Previous Close | 7.04 |
| Open | 7.05 |
| Bid | 6.94 x 1000 |
| Ask | 6.96 x 1000 |
| Day's Range | 6.89 - 7.11 |
| 52 Week Range | 5.13 - 11.49 |
| Volume | 25,556 |
| Avg. Volume | 52,335 |
| Market Cap | 199.605M |
| Beta (3Y Monthly) | 2.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
TEL-AVIV, Israel and RALEIGH, N.C., June 10, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a new patent covering RHB-104 for Crohn’s disease and RHB-204 for Mycobacterium avium complex (MAC) disease, the most common cause of pulmonary nontuberculous mycobacteria (NTM) infections1. Once granted, the patent is expected to be valid until at least 2029.
TEL-AVIV, Israel and RALEIGH, N.C., May 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced the appointment of Dr. June S. Almenoff, M.D., Ph.D., FACP, as Chief Scientific Officer. Dr. Almenoff, an accomplished pharma executive with extensive gastroenterology and infectious diseases expertise, will lead the Company’s commercial strategy as it relates to medical and scientific matters, including the medical affairs activities for Talicia® (RHB-105)1 in preparation for potential U.S. commercial launch in the fourth quarter of 2019.
TEL-AVIV, Israel and RALEIGH, N.C., May 23, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. Adi Frish, Senior Vice President of Business Development and Licensing, will present a corporate overview at the 2019 BIO International Convention on Monday, June 3, 2019, at 1:30 p.m. EDT at the Pennsylvania Convention Center, Philadelphia, PA. A copy of the presentation to be delivered by Mr. Frish will be available on the Company's website and may be viewed at: http://ir.redhillbio.com. RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company, primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases.
TEL-AVIV, Israel and RALEIGH, N.C., May 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that it is expanding its commercial management team with several key executive hires ahead of the potential U.S. launch of Talicia®. The Company has appointed Rob Jackson as Vice President of Marketing, Robert J. Gilkin, Jr. as Vice President of Market Access and Steven Thomasian as Vice President of Supply Chain.
Key Highlights and Upcoming Milestones: NDA submitted to the FDA for Talicia® for H. pylori infection, with potential U.S. commercial launch in Q4/2019, assuming FDA.
TEL-AVIV, Israel and RALEIGH, N.C., May 07, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that, following a positive pre-NDA meeting held recently with the U.S. Food and Drug Administration (FDA), it has submitted a New Drug Application (NDA) to the FDA for Talicia® (RHB-105)1 for the treatment of H. pylori infection. The NDA was submitted under the 505(b)(2) regulatory pathway.
TEL-AVIV, Israel and RALEIGH, N.C., April 30, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that it will report its first quarter 2019 financial results and operational highlights on Tuesday, May 7, 2019. The Company will host a conference call on Tuesday, May 7, 2019 at 8:30 a.m. EDT to review the financial results and operational highlights. The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, http://ir.redhillbio.com/events.
TEL-AVIV, Israel and RALEIGH, N.C., April 04, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.
TEL-AVIV, Israel and RALEIGH, N.C., March 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. Adi Frish, senior vice president of business development and licensing, will present a corporate overview at the BIO-Europe Spring 2019 conference on Wednesday, March 27, 2019, at 9:45 a.m. CET at the Messe Wien Exhibition and Congress Center in Vienna, Austria. A copy of the presentation to be delivered by Mr. Frish will be available on the Company's website and may be viewed at: http://ir.redhillbio.com.
TEL-AVIV, Israel and RALEIGH, N.C., March 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. Adi Frish, senior vice president of business development and licensing, will present a corporate overview at the 31st Annual ROTH Conference on Tuesday, March 19, 2019, at 1:00 p.m. PDT at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. The presentation will be broadcast live and available via replay for 30 days on the Company's website, http://ir.redhillbio.com/events.
The European and Japanese patent applications have been accepted and, once granted, are expected to be valid until 2034 U.S. NDA for Talicia® on track for potential submission.
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 26, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it will report its full-year 2018 financial results and operational highlights on Tuesday, February 26, 2019. The Company will host a conference call on Tuesday, February 26, 2019 at 8:30 a.m. EST to review the financial results and business highlights.
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 20, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today announced that it has strengthened its commercial management team by appointing board member, Mr. Rick D. Scruggs as chief operating officer, U.S. operations. Mr. Scruggs is responsible for leading the Company’s U.S. commercial operations, currently promoting four GI products, and the preparations for the potential commercial launch of TALICIA® (RHB-105)1 for eradication of H. pylori infection, planned for the fourth quarter of 2019.
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today announced that Mr. Dror Ben-Asher, chief executive officer of RedHill, will present a corporate overview at the 8th Annual SVB Leerink Healthcare Conference on Friday, March 1, 2019, at 9:30 a.m. EST, at the Lotte New York Palace, New York.
Notice of Allowance received and, once granted, the new U.S. patent is expected to be valid until 2034NDA submission is expected in H1/2019, with eligibility for 6-month.
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 11, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the closing of its previously announced underwritten public offering for a total number of 2,857,143 American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, at a public offering price of $7.00 per ADS. The Company has also granted the underwriters a 30-day option to purchase up to 428,571 additional ADSs at the public offering price.
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 06, 2018 -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty.
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 04, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it intends to offer its American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ADSs offered to the public. The Company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund preparations for TALICIA® (H. pylori) commercial launch and commercialization activities, clinical development programs, including initiation of a pivotal Phase III study with RHB-204 for NTM, preparations for a second Phase III study with RHB-104 for Crohn’s disease and for acquisitions and general corporate purposes.
The ERADICATE Hp2 confirmatory Phase 3 study successfully met its primary endpoint of H. pylori eradication (84% vs. 58%) with high degree of statistical significance.
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that Mr. Dror Ben-Asher, chief executive officer of RedHill, will present a corporate overview at the BMO 2018 Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018, at 3:00 p.m. EST at the Mandarin Oriental Hotel, New York.
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases and cancer, today announced a poster presentation on YELIVA® (opaganib, ABC294640)1 for multiple myeloma at the upcoming EORTC-NCI-AACR Symposium2 on Molecular Targets and Cancer Therapeutics, on Friday, November 16th in Dublin.
Key Highlights: Top-line results from the confirmatory Phase III study with TALICIA® for H. pylori infection are on track to be announced by year-end 2018, with potential NDA.
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it will report its third quarter 2018 financial results on Tuesday, November 13, 2018. The Company will host a conference call on Tuesday, November 13, 2018 at 8:30 a.m. EST to review the financial results and business highlights.